Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia

Clinical and Laboratory Haematology

Volumn 28, Issue 3, 2006, Pages 208-210

  Zaucha, J M ^a,b   Wyrowinska, E ^b   Prejzner, W ^a   Calbecka, M ^b   Hellmann, A ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Regional Hospital   (Poland)

Author keywords

Chronic myeloid leukaemia; Imatinib; Myelosuppression

Indexed keywords

ALLOPURINOL; FUROSEMIDE; IMATINIB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; ARTICLE; BLAST CELL CRISIS; BONE MARROW SUPPRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; MEDICAL DECISION MAKING; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TREATMENT WITHDRAWAL;

ANTINEOPLASTIC AGENTS; BLAST CRISIS; FEMALE; FILGRASTIM; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MIDDLE AGED; NEUTROPENIA; PIPERAZINES; PYRIMIDINES;

EID: 33646721928     PISSN: 01419854     EISSN: 13652257     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2006.00772.x     Document Type: Article

References (7)

1. Cortes J., O'Brien S. Kantarjian H. 2004 Discontinuation of imatinib therapy after achieving a molecular response. Blood 104, 2204 2205.
2. Deininger M.W., O'Brien S.G., Ford J.M. Druker B.J. 2003 Practical management of patients with chronic myeloid leukemia receiving imatinib. Journal of Clinical Oncology 21, 1637 1647.
3. Kantarjian H.M., Cortes J., O'Brien S., Giles F.J., Albitar M., Rios M.B., Shan J., Faderl S., Garcia-Manero G., Thomas D.A., Resta D. Talpaz M. 2002 Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99, 3547 3553.
4. Marin D., Marktel S., Bua M., Szydlo R.M., Franceschino A., Nathan I., Foot N., Crawley C., Na Nakorn T., Olavarria E., Lennard A., Neylon A., O'Brien S.G., Goldman J.M. Apperley J.F. 2003 Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 17, 1448 1453.
5. Quintas-Cardama A., Kantarjian H., O'Brien S., Garcia-Manero G., Rios M.B., Talpaz M. Cortes J. 2004 Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 100, 2592 2597.
6. Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., Schiffer C.A., Talpaz M., Guilhot F., Deininger M.W., Fischer T., O'Brien S.G., Stone R.M., Gambacorti-Passerini C.B., Russell N.H., Reiffers J.J., Shea T.C., Chapuis B., Coutre S., Tura S., Morra E., Larson R.A., Saven A., Peschel C., Gratwohl A., Mandelli F., Ben-Am M., Gathmann I., Capdeville R., Paquette R.L. Druker B.J. 2002 Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99, 3530 3539.
7. Terre C., Eclache V., Rousselot P., Imbert M., Charrin C., Gervais C., Mozziconacci M.J., Maarek O., Mossafa H., Auger N., Dastugue N., Talmant P., Van den Akker J., Leonard C., Khac F.N., Mugneret F., Viguie F., Lafage-Pochitaloff M., Bastie J.N., Roux G.L., Nicolini F., Maloisel F., Vey N., Laurent G., Recher C., Vigier M., Yacouben Y., Giraudier S., Vernant J.P., Salles B., Roussi J., Castaigne S., Leymarie V., Flandrin G. Lessard M. 2004 Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18, 1340 1346.